IDYA vs TPVG vs AGEN vs IMVT vs KYMR

For growth investors, IDEAYA Biosciences, Inc.

(IDYA) is the stronger pick with 30. 2% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 6x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate IDEAYA Biosciences, Inc. (IDYA) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Agenus Inc.

is actually cheaper at 1. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +110. 5%, compared to -93. 1% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus AGEN's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 83β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 227% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEAYA Biosciences, Inc.

(IDYA) is pulling ahead at 30. 2% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, IDYA leads at 62. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 9x forward P/E versus 6. 0x for TriplePoint Venture Growth BDC Corp. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDYA: 104. 1% to $58. 67.

In this comparison, TPVG (18.

4% yield) pays a dividend. IDYA, AGEN, IMVT, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 18. 4% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +87. 8%, AGEN: -93. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IDYA (Healthcare) and TPVG (Financial Services) and AGEN (Healthcare) and IMVT (Healthcare) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IDYA is a small-cap high-growth stock; TPVG is a small-cap high-growth stock; AGEN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock. TPVG pays a dividend while IDYA, AGEN, IMVT, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.